Industry Insight
Information, Observation & Analysis
The adoption of ASPs has resulted in a reduction of antimicrobial expenditures, but stopping the tide of multidrug-resistant organisms depends on leadership’s commitment to track data down to the patient level.
The glut of soon-to-expire products within the pharmaceutical supply chain is a costly problem impacting multiple stakeholders, but smart technology and innovative inventory management systems offer cost-saving solutions.
Reimbursement for expensive immune globulin (IG) therapies can be challenging and frustrating for providers. Here's a guide to help ensure they are reimbursed for the cost of these medications.
Healthcare costs continue to rise and payment models subsequently evolve, payers nevertheless largely decide which expensive high-investment drugs will be reimbursed and under what circumstances.
Demand for IG products has doubled, going from 3 million grams just a decade ago to 7 million grams year-over-year today. What is to account for this increase?